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Introduction
Thirteen-years-old, I remember riding to school in my older 
brother’s car. Darrin and I had never been terribly close, often 
fighting during our childhood, yet a 2011 album by Mac Miller 
called Blue Slide Park gave us a reason to bond. As we knew 
nobody else in our family was interested in rap of any kind, 
Darrin and I would frequently send each other videos of the 
hip hop singer and his latest releases. This artist brought us 
together through my adolescence and into adulthood. In Sep-
tember of 2018, Mac Miller died in his home after an accidental 
overdose of fentanyl, cocaine, and alcohol. Fentanyl, an opi-
oid used for pain relief, is one of the many prescription drugs 
contributing to the opioid crisis through abuse and misuse. I 
believe Mac Miller’s talents as an artist and his contributions to 
the work of other rap artists were unparalleled. Yet, the artist 
means more to me because of how his music strengthened 
the relationship I have with my brother. I cannot help but think 
of the pain I felt from his death, compared to the pain of those 
who have lost loved ones, family members, and friends to 
opioid overdose and addiction. Over the past 30 years, opioid 
misuse has become a serious public health crisis. In order to 
fully evaluate the crisis and develop solutions to combat it, the 
problem of opioid abuse must be considered in its entirety. 
The opioid crisis has had a devastating impact on the United 
States population, and extensive efforts to develop awareness 
through education along with research toward finding solu-
tions are needed to decrease the morbidity and mortality of 
this epidemic. 
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The Problem 
Every year, deaths due to opioid misuse continues to 
rise. From July 2016 to September 2017, opioid overdoses 
increased by 30%. In certain regions, including the Midwest, 
the increase during this same period was nearly 70% (National 
Institute on Drug Abuse). With that in mind, the United States 
prescribes 80% of the world’s opioids (Rathmell and Khar-
asch 866). This problem continues to escalate, affecting more 
people each year, and reforms need to be made to the cur-
rent prescribing methods of physicians and toward improving 
patient education. The crisis has become more severe as the 
market for prescription opioids grows, and with many physi-
cians feeling pressured to treat pain aggressively with opioids 
(Cicero 1322). Patients are often overprescribed an opioid to 
manage pain, leading to dependence. The high potential for 
dependence is why it is important for physicians to first at-
tempt other effective treatment options to ensure opioids are 
only prescribed with necessary cases. If a patient’s pain can be 
managed with non-opioid treatment options, it may be safer to 
utilize those treatments prior to opioid therapy. 
Overdose is the leading cause of opioid related death, 
particularly among Americans. While overdoses can be unin-
tentional, the number of opioid related suicides has increased 
from 17% in 2000 to 41% in 2017  (University of Michigan). 
With rates of both unintentional and intentional deaths caused 
by opioid misuse increasing in the United States, it is clear that 
many who suffer from opioid-use-disorder are not receiving 
proper treatment. Some European countries, such as Switzer-
land, have better treatment rates and provide an example that 
the United States could model. In the United States, less than 
22% of patients suffering from opioid-use-disorder received 
treatment between 2009 and 2013, while in Switzerland 71% 
to 88% of the coextensive population received treatment 
(Vokinger 189). Lack of treatment in the United States may 
directly correlate to the increasing death rates associated with 
the opioid crisis. Without a critical analysis of this crisis, the 
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death toll will continue to rise. Understanding the demo-
graphic predictors of opioid addiction and misuse, accessibil-
ity of treatment, and the pharmacology of opioids is neces-
sary to evaluate the crisis and suggest proper educational and 
medical reform. 
At-risk Population
Examining the disparities that are characteristic of at-risk 
populations will allow for the development of more targeted 
solutions for education, treatment, and prevention efforts. Amy 
S.B. Bohnert and Mark A. Ilgen from the Department of Psychi-
atry at the University of Michigan state that more research is 
needed “to identify who’s most at risk of deliberate or unin-
tentional opioid overdoses, to make sure these individuals 
get better pain management, mental health care and medica-
tion-assisted therapy for opioid addiction.” Identifying at-risk 
populations could allow for adjustment of health efforts and 
lead to a decrease in opioid overdose in these populations. In 
addition, identifying at-risk populations can lead to uncover-
ing trends that will focus future treatment efforts. A 2015 drug 
use and health survey classified and evaluated prescription 
opioid use by demographics in the United States. The survey 
found that prescription opioid overdose deaths have quadru-
pled between 1999 and 2015 (Han, Compton et al. 293). This 
survey found information about the risk factors associated with 
prescription opioid misuse in the United States. The general 
trends indicate that men are more at-risk of opioid misuse than 
women, the family income of affected individuals generally 
falls below $20,000 yearly, and the most impacted individuals 
are between the ages of 18 to 29 years-old (Han, Compton et 
al. 296). Therefore, poor, young males are disproportionately 
affected by the opioid crisis. While it is important to identify risk 
factors for opioid abuse, it is also important to note that any 
person can experience addiction, and those affected deserve 
proper treatment. 
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Risk Factors
Risk factors for opioid addiction have been recognized 
through several research studies. An article published in The New 
England Journal of Medicine identified additional correlations. 
The research found that women below the age of 65 are more 
likely to unintentionally overdose compared to other demograph-
ic groups (Bohnert and Ilgen). This may be because women, on 
average, are physically smaller than men, and smaller body-mass 
may increase their susceptibility for an opioid related overdose. It 
was also found that opioid misuse is correlated with age and race. 
Generally, older black men are more likely to misuse opioids than 
older white men, while young white men are more likely to misuse 
opioids than young black men (Bohnert and Ilgen). Knowing 
these risk factors is important for healthcare providers to develop 
targeted prevention efforts and overdose treatments for their pa-
tients. For example, a physician informing a female opioid addict 
that she is more likely to overdose than any other demographic 
could potentially motivate the patient to continue and maintain 
treatment for the addiction. Although poor, young, males are dis-
proportionally impacted by this crisis, those from all backgrounds 
may be at-risk as well due to the current over-prescription of 
opioids in healthcare today.
Pharmacology of Opioids
Development of drugs for treating opioid addiction was 
made possible by research into the physiology of opioid inter-
actions. Drug developers have identified the central pathways 
through which opioids work, and the blocking of these pathways 
allows for multiple effective treatment options. Opioids bind three 
transmembrane neurotransmitter receptors: μ (Mu), κ (Kappa), 
and δ (Delta). Mu is the transmembrane receptor that is clinically 
significant as opioid binding of this receptor modulates neu-
rotransmitter transmission. Opioids inhibit neurotransmission 
through the nociceptive pathways of pain perception (Strain). Opi-
oids function at both the presynaptic and postsynaptic neurons.
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Starting at the pre-synapse, opioids act antagonistically by 
binding to the Mu G-Coupled Protein Receptors, closing the 
voltage-gated calcium channels by hyperpolarizing, increasing, 
the cells membrane potential. When the voltage-gated calcium 
channels are closed, the calcium concentration inside the cell 
decreases, reducing the release of neurotransmitter into the 
synaptic cleft. With fewer nociceptive impulses sent, the patient 
feels the analgesic effect of the drug (Strain). Antagonistic 
drugs to treat opioid misuse include Naltrexone (Traynor 254) 
and Naloxone (National Institute on Drug Abuse). Naltrexone 
does not have “intrinsic activity,” meaning that when it binds 
to the opioid receptor it does not induce the same effect as an 
opioid (Raffa, Taylor, and Pergolizzi 860). Naltrexone acts as a 
competitor for the opioid binding site, reducing the number of 
receptors that respond to opioids the opioid initiated pathway 
(see Figure 1). 
Figure 1: Mechanism of Action of Naltrexone
Naltrexone takes place of an agonist that would create 
opioid-like effect. 
Source: Raffa, Taylor, and Pergolizzi. “Naltrexone 
 Extended-Release Injection: an Option for 
 the Management of Opioid Abuse.” 
 Substance Abuse and Rehabilitation, 5 Dec. 
 2011, p. 219., doi:10.2147/sar.s17920. 
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At the post-synapse, opioids act as agonists by binding 
to Mu G-Coupled Protein Receptors, stimulating the release 
of potassium via the opening of voltage-gated potassium 
channels. This efflux of potassium leads to hyperpolarization, 
preventing an action potential from being generated, thereby 
inhibiting transmission of the nociceptor (Strain). Prescription 
agonists to treat opioid misuse include Methadone and Bu-
prenorphine (Traynor 254). Buprenorphine is a partial agonist 
of the mu-opioid receptor, with efficient binding but limited 
effects in terms of receptor activation (see figure 2) (Pillarisetti 
and Khanna 860). This opioid can compete with a stronger opi-
oid like morphine for the binding site, yet provide the analge-
sic effect that addicts want. 
Figure 2: Mechanism of Action of Buprenorphine
Buprenorphine demonstrates a partial agonism responsible for reduced opioid 
dependence and analgesia. 
Source: Pillarisetti, Sivaram, and Ish K Khanna. “Buprenorphine – an Attractive 
 Opioid with Underutilized Potential in Treatment of Chronic Pain.” 
 Journal of Pain Research, 4 Dec. 2015, doi:https://doi.org/10.2147/
 JPR.S85951. 
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Pharmacologists use their understanding of the mechanisms 
behind the of action of opioids to create better pain management 
drugs. Traditionally, it was thought that all opioids activated the 
same downstream pathway, but this simplistic view has been re-
placed by a model of functional selectivity. This model describes 
how Mu receptors either activate G-Coupled Protein Receptors 
or receptors in the Beta-Arrestin pathway. The American Soci-
ety of Anesthesiology states: “Even more exciting is the discov-
ery that various opioids can selectively confer more activity in 
one pathway than another, called ‘biased agonism’ or ‘function-
al selectivity’“ (Rathmell and Kharasch 866). If the G-Coupled 
Protein Receptor pathway can be targeted for pain manage-
ment, the negative effects of the Beta-Arrestin pathway can be 
mitigated (Rathmell and Kharasch 866). Negative effects asso-
ciated with the Beta-Arrestin pathway, as well as with opioids 
in general, include shallow breathing and the development of 
tolerance. The competitive agonism of opioid pathways can 
be exploited to mitigate the negative effects of opioids, and 
further research may lead to more effective treatment for those 
abusing opioids.
Treatment Access
Despite the wide variety of treatment options, access to 
effective treatment is often difficult for those within the at-risk 
population. Treatment access tends to be limited and “those 
with opioid use disorder are young and more likely to be un-
employed, either uninsured or relying on Medicaid, and other 
public funding mechanisms, than those without substance use 
disorders” (Becker 210). There are a few widely used treatment 
options for opioid addiction that help to mitigate the symp-
toms of addiction or reverse overdose. The first treatment op-
tion is buprenorphine, which treats the actual opioid addiction 
by preventing the undesirable consequences of withdrawal 
(Traynor 254). Patients are given smaller and smaller doses of 
buprenorphine, in a controlled manner, to wean them off opi-
oids without sending their body into shock. Methadone is also 
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prescribed in a similar fashion. However, because these drugs 
may be abused as well, Hillary Connery writes in the Harvard 
Review of Psychiatry that this option could be “used illicitly, 
resulting in further opioid misuse and overdoses” (Connery 69). 
Additionally, naltrexone is used to block “the euphoric effects 
of opioids to prevent relapse in patients who have completed 
detoxification and are no longer physically dependent on opi-
oids” (Traynor 254). These drugs increase the options available 
for practitioners to include in a treatment regimen to reduce 
the tendency of relapse. Furthermore, Naloxone (generic: 
Narcan) may be an effective treatment for reversing an acute 
overdose (Bohnert and Ilgen). Naloxone rapidly eliminates opi-
oids from the body causing potentially aggressive withdrawal 
symptoms. For this reason, Naloxone is only administered 
during acute, life-threatening situations. With multiple effective 
treatment options, there should be greater opportunities for 
treatment of individuals misusing opioids. 
Potential Solutions
Increased treatment of those misusing opioids will require 
reduced stigmatization of opioid addiction, increased educa-
tion nationwide, and increased political action to address the 
problem. Increased treatment rates may lead to better out-
comes within the United States population, reducing the opioid 
crisis. Currently, there is much talk about the opioid crisis in the 
media and in politics, but more work needs to be done. The 
United States presidential administration declared the opioid 
crisis a public health emergency in October of 2017, and this 
declaration was renewed in October of 2018 (Azar II). Although 
this statement of a public health emergency was a promising 
stride toward change, it only served to reallocate funds and of-
fered no tangible solutions. Instead, there must be comprehen-
sive initiatives enacted by political leaders to improve health 
outcomes of those affected by opioid misuse. 
Those that hold the power to make public health initiatives, 
fund research, and advocate for treatment of those impacted 
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by opioid misuse should be passionate and informed, or this 
crisis will only worsen. For example, the Canada Health Journal 
describes the need for novel approaches to data collection to 
find risk factors and trends, as well as improve treatment rates. 
The journal explains, “The Office of Drug Research and Sur-
veillance is working with the Canadian Surveillance System for 
Poison Information on harmonizing call data collected by poi-
son control centers to capture details on drug-related harms, 
including due to opioid related overdoses (Abdesselam, Dann 
and Alwis 315).” The collected data has provided Canada with 
more useful information that could lead to a deeper under-
standing of opioid use and misuse. Efforts like this should be 
modelled in the United States to lead to data driven public 
health initiatives. Political awareness is the responsibility of 
every citizen of the United States and may lead to better out-
comes for those suffering from opioid addiction. Research and 
public health initiatives happen when citizens vote for officials 
who are invested in change and will advocate for solutions at a 
nationwide level. 
Education on the opioid crisis can take many different 
forms, and should be included in medical school curriculums.  
The education of doctors who prescribe opioids should be 
comprehensively covered in medical school and continu-
ing-education should be provided for those in practice. Theo-
dore Cicero describes the necessity of a risk-benefit ratio when 
prescribing opioids, arguing that prescribing fewer opioids 
is not always beneficial and that opioids are often therapeuti-
cally necessary (Cicero 1323). The opioid epidemic cannot be 
solved by simply reducing the number of prescribed opioids. 
In a National Survey of Drug Use and Health, Han, Compton, et 
al. write: “Simply restricting access to opioids without offering 
alternative pain treatments may have limited efficacy in re-
ducing prescription opioid misuse and could lead people to 
seek prescription opioids outside the health system or to use 
nonprescription opioids, such as heroin or illicitly made fentanyl, 
which could increase health, misuse, and overdose risks ” (Han, 
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Compton, et al 299). Simply put, turning people away from 
pain treatment is not the right path as many people will turn to 
illicit opioids for relief, an alternative that could be life threaten-
ing. Instead, treatment rates for those suffering from addiction 
need to increase, access to non-addictive pain medication 
must increase, and excessive prescribing of opioids that could 
be misused needs to be reduced (Han, Compton, et al 293). 
Within pharmacology, there must be an expansion of exist-
ing pharmacologic resources to mitigate the cycle of opioid 
over-prescription and education for healthcare practitioners 
with respect to opioid treatments (Rathmell and Kharasch 866).
In addition to better training for physicians, the stigma for 
those seeking opioid addiction treatment needs to be dispelled. 
In order to change this stigma, there must be nationwide educa-
tion efforts to reinforce the importance of treatment for opioid 
misuse. Kerstin Vokinger remarks in The Journal of Law, Medicine 
and Ethics that those addicted to opioids are not weak, lacking 
morality, or doing it “on-purpose” but this is often how they are 
treated (Vokinger 189). Those who want treatment would feel 
less shame and be more likely to take the necessary steps to get 
help with community support. To reduce the number of individ-
uals affected by the opioid crisis, as well as increase treatment, 
limit overdoses, and reduce addiction, there must be education 
and informational campaigns on multiple fronts. Natalia Morone 
and Debra Weiner advocate for pain education and training in 
Clinical Therapeutics. Morone and Weiner describe the fifth vital 
sign of pain and how practitioners are trained to respond to pain 
(Morone and Weiner 1730). Education efforts could use cases of 
chronic pain management to educate the medical professionals 
about “a comprehensive, multidimensional approach that also 
reviews pain theory, the physical examination, and management 
of the various contributors to pain” (Morone and Weiner 1730). 
Education efforts, such as those purposed by Morone and Weiner, 
may possibly reduce over prescribing of opioids and reverse the 
trend of misuse. With widespread education, awareness, under-
standing, and funding may follow, eventually leading to change.
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Conclusion
With a vast number of opioid overdoses and low treat-
ment rates, it is clear that the opioid crisis is a critical issue in 
the United States. In 2017, more than 70,200 Americans died 
from opioid overdoses and within the past decade, there has 
been a two-fold increase in opioid overdose rates (National 
Institute on Drug Abuse). Not enough action being taken 
today to stop the epidemic and a lack of resources dedicated 
to researching alternate drugs as well as identifying means 
to target at risk populations hinder this progress. While some 
populations are at higher risk for opioid addiction and over-
dose, it is important to note that opioid misuse is a problem 
for people in all walks of life: young and old, men and wom-
en, as well as rich and poor.
 An effective treatment for opioid addictions are count-
er-drugs. Many drugs are known to target different aspects 
associated with addiction. Naltrexone targets the antagonistic 
pathway and may help reverse an opioid overdose, preventing 
relapse. Buprenorphine and methadone are opioid agonists 
that can wean a patient from opioid dependency. In spite of 
the availability of these effective treatment methods, few users 
seek treatment (Becker 210). With low treatment rates across 
the United States, there is room for improved screening for opi-
oid use, coupled with treatment of those who are found mis-
using. If a person misusing opioids does not receive treatment 
for their addiction, their dependency often worsens, eventually 
resulting in an overdose. Initiatives enacted in other countries 
have resulted in increased treatment rates. These plans could 
be used as models to improve treatment rates in America. In 
healthcare, education for new drugs that could provide pain 
relief without the negative effects of opioids, treatment options 
for those who are struggling with misuse, and education for 
those that are addicted to seek help and remain clean. Further-
more, public-wide education efforts are needed to recognize 
an overdose, understanding of the dangers of taking opioids 
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that are not prescribed, and the risk of overdose when mis-
using opioids. These items will require funding, and start with 
elected United States officials. Elected leaders must advocate, 
allocate funding, and have the initiative to enact change in 
the nation’s approach to opioids. Opioid misuse, addiction, 
and overdose rates are increasing every year. There must be 
continued education efforts, productive legislation, and funded 
research to reverse this trend. 
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